Application and Effect
Leflunomide is inactive, but teriflunomide inhibits pyrimidine de novo synthesis at low therapeutic doses by inhibiting dihydroorotate dehydrogenase (the rate-determining enzyme for the synthesis of UMP), decreasing DNA and RNA synthesis, and arresting the cell proliferation cycle and production of antibodies. The reduction of dihydroorotate to orotate occurs concurrently with the reduction of its cofactor, ubiquinone (coenzyme Q). The inhibition of dihydroorotate dehydrogenase by teriflunomide demonstrates noncompetitive and uncompetitive kinetics. Administration of leflunomide in patients with rheumatoid arthritis results in progressive removal of B cells and down-regulation of the immune process.Product Sample
Product Packing:
Additional Information:
| Composition | C12H9F3N2O2 |
| Assay | 99% |
| Appearance | White powder |
| CAS No. | 75706-12-6 |
| Packing | 25KG |
| Shelf Life | 2 years |
| Storage | Store in cool and dry area |
| Certification | ISO. |